Skip Navigation

Cardiovascular Research 2006 69(3):736-745; doi:10.1016/j.cardiores.2005.08.009
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Spallarossa, P.
Right arrow Articles by Barsotti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spallarossa, P.
Right arrow Articles by Barsotti, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase

Paolo Spallarossaa,1, Paola Altieria,*,1, Silvano Garibaldia, Giorgio Ghigliottia, Chiara Barisionea, Valeria Mancaa, Patrizia Fabbia, Alberto Ballestrerob, Claudio Brunellia and Antonio Barsottia

aResearch Center of Cardiovascular Biology, Department of Cardiology, University of Genova, Viale Benedetto XV, 6 16132 Genova, Italy
bDepartment of Internal Medicine, University of Genova, 16132 Genova, Italy

* Corresponding author. Tel.: +39 0103537990; fax: +39 0103538655. Email address: paola.altieri{at}unige.it

Objective: Dysregulation of myocardial metalloproteinases (MMPs) is now regarded as an early contributory mechanism for the initiation and progression of heart failure. Doxorubicin is a strongly cardiotoxic anticancer drug. This study investigates the effects of doxorubicin on myocardial MMP-2 and MMP-9 activation.

Methods: After pre-treatment with or without carvedilol or dexrazoxane, we exposed H9c2 cardiomyocytes to doxorubicin to evaluate reactive oxygen species (ROS) formation and MMP-2 and MMP-9 expression and activation. To investigate the signaling pathways leading to doxorubicin-induced MMP activation, we also examined the phosphorylation of three members of the MAPK family (ERK1/2, p38, and JNK), the effects of selective inhibitors of ERK1/2, p38, and JNK on MMP transcription and activity, the transcription of the NAD(P)H oxidase subunit Nox1, and the effects of the NAD(P)H oxidase inhibitor DPI on MMP activation.

Results: Doxorubicin induces a significant increase in ROS formation and a rapid increase of MMP expression and activation. Pre-treatment with carvedilol or dexrazoxane prevented these effects. We also found that p38 is the MAPK that is mainly responsible for MMP-9 activation through an NAD(P)H-independent mechanism. ERK and JNK modulate the transcription of the NAD(P)H oxidase subunit Nox1, while the JNK/ERK NAD(P)H oxidase cascade is an important pathway that mediates doxorubicin signaling to MMP-2. Inhibition of NAD(P)H oxidase attenuates the increase in MMP-2, but augments the doxorubicin-induced increase in MMP-9.

Conclusions: Enhancement of MMP-2 and MMP-9 in cardiac myocytes in response to doxorubicin is mediated by the cooperation of ERK, JNK, and p38 kinase pathways, most of which are redox dependent.

KEYWORDS Matrix metalloproteinases; Myocytes; MAP kinase; NADPH oxidase; Oxygen radicals


1 Both authors contributed equally to this study.

Time for primary review 9 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Y. Zhang, J. C. Naggar, C. M. Welzig, D. Beasley, K. S. Moulton, H.-J. Park, and J. B. Galper
Simvastatin Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-Knockout Mice: Possible Role of ERK
Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1764 - 1771.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. D. Kandasamy and R. Schulz
Glycogen synthase kinase-3{beta} is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts
Cardiovasc Res, September 1, 2009; 83(4): 698 - 706.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, L. Liaudet, C. Szabo, and P. Pacher
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro
Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1466 - H1483.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F. Bogazzi, D. Russo, F. Raggi, F. Ultimieri, C. Urbani, M. Gasperi, L. Bartalena, and E. Martino
Transgenic Mice Overexpressing Growth Hormone (GH) Have Reduced or Increased Cardiac Apoptosis through Activation of Multiple GH-Dependent or -Independent Cell Death Pathways
Endocrinology, November 1, 2008; 149(11): 5758 - 5769.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Liu, W. Mao, B. Ding, and C.-s. Liang
ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes
Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1956 - H1965.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Kim, Y.-S. Lee, J. Choe, H. Lee, Y.-M. Kim, and D. Jeoung
CD44-Epidermal Growth Factor Receptor Interaction Mediates Hyaluronic Acid-promoted Cell Motility by Activating Protein Kinase C Signaling Involving Akt, Rac1, Phox, Reactive Oxygen Species, Focal Adhesion Kinase, and MMP-2
J. Biol. Chem., August 15, 2008; 283(33): 22513 - 22528.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. LaCroix, J. Freeling, A. Giles, J. Wess, and Y.-F. Li
Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H810 - H820.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
H. Aupperle, J. Garbade, A. Schubert, M. Barten, S. Dhein, H.-A Schoon, and F.-W Mohr
Effects of Autologous Stem Cells on Immunohistochemical Patterns and Gene Expression of Metalloproteinases and Their Tissue Inhibitors in Doxorubicin Cardiomyopathy in a Rabbit Model
Vet. Pathol., July 1, 2007; 44(4): 494 - 503.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T.-N. Zhu, H.-J. He, S. Kole, T. D'Souza, R. Agarwal, P. J. Morin, and M. Bernier
Filamin A-mediated Down-regulation of the Exchange Factor Ras-GRF1 Correlates with Decreased Matrix Metalloproteinase-9 Expression in Human Melanoma Cells
J. Biol. Chem., May 18, 2007; 282(20): 14816 - 14826.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. Martinson, M. P. Hans, G.-D. David, and A. M. Elizabeth
Readers' choice: Hot papers downloaded in 2006
Cardiovasc Res, March 1, 2007; 73(4): 619 - 622.
[Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
D. J. H. Mountain, M. Singh, B. Menon, and K. Singh
Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKC{alpha}/beta1 and MAPKs
Am J Physiol Cell Physiol, February 1, 2007; 292(2): C867 - C875.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Ito, Y. Fujio, K. Takahashi, and J. Azuma
Degradation of NFAT5, a Transcriptional Regulator of Osmotic Stress-related Genes, Is a Critical Event for Doxorubicin-induced Cytotoxicity in Cardiac Myocytes
J. Biol. Chem., January 12, 2007; 282(2): 1152 - 1160.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. C. Newby, M. Pauschinger, and F. G. Spinale
From tadpole tails to transgenic mice: Metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease
Cardiovasc Res, February 15, 2006; 69(3): 559 - 561.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.